Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients
Abstract
Background Both human and animal studies suggest oxytocin may have antipsychotic properties. Therefore, we conducted a clinical trial to directly test this notion.Methods Nineteen schizophrenia patients with residual symptoms despite being on a stable dose of at least one antipsychotic were enrolled in a randomized, double-blind, crossover study. They received 3 weeks of daily intranasal oxytocin (titrated to 40 IU twice a day) and placebo adjunctive to their antipsychotics. Order of intranasal treatment was randomly assigned and there was a 1-week washout between treatments.Results Analysis of the 15 subjects who completed all the study visits revealed that oxytocin significantly reduced scores on the Positive and Negative Symptom Scale (p < .001) and Clinical Global Impression-Improvement Scale (p < .001) compared with placebo at the 3-week end point. No benefit was seen at the early time points. Oxytocin was well tolerated and produced no adverse effects based upon patient reports or laboratory analysis.Conclusions The results support the hypothesis that oxytocin has antipsychotic properties and is well tolerated. Higher doses and longer duration of treatment may produce larger benefits and should be evaluated in future studies.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The acute increase in pro-social behavior, specifically time spent in contact, in male prairie voles following intranasal oxytocin resembles findings in many human studies.
“The acute effects of intranasal OT that we found here resemble those found in many human studies, consisting of an increase in pro-social behavior and engagement (specifically time spent in contact in males)(13,15,64–66).”
From Chronic intranasal oxytocin causes long-term impairments in partner preference formation in male prairie voles (2013) · cites this paper as [66]
Similar doses of oxytocin have been administered to subjects in previous studies of social functioning.
“Similar doses of OT have been administered to subjects in previous studies of social functioning (Andari et al., 2010; Feifel et al., 2010; Guastella et al., 2008; Hollander et al., 2007; Ditzen et al., 2009).”
From Effects of intranasal oxytocin on social anxiety in males with fragile X syndrome (2012) · cites this paper as Feifel et al., 2010
In patients with schizophrenia, an adjunctive 3-week treatment with intranasal OXT significantly improves Positive and Negative Syndrome Scale (PANSS) total scores and verbal memory measures of the California Verbal Learning Test.
“Furthermore, in patients with schizophrenia, an adjunctive 3-week treatment with intranasal OXT has been found to significantly improve Positive and Negative Syndrome Scale (PANSS) total scores (Feifel et al, 2010) and verbal memory measures of the California Verbal Learning Test (Feifel et al, 2012a).”
From Chronic and acute intranasal oxytocin produce divergent social effects in mice (2014) · cites this paper as Feifel et al, 2010
The efficacy of oxytocin administration depends on dosage.
“it has been proposed that the efficacy of oxytocin administration depends on dosage.10, 12, 13”
From Oxytocin efficacy is modulated by dosage and oxytocin receptor genotype in young adults with high-functioning autism: a 24-week randomized clinical trial (2016) · cites this paper as [12]
A dose of 40 IU oxytocin twice a day is comparable to the doses previously used in human studies investigating effects of multiple treatments of oxytocin and does not produce significant side effects or adverse outcomes.
“A dose of 40 IU twice a day is comparable to the doses previously used in human studies investigating effects of multiple treatments of oxytocin [61,62] and does not produce significant side effects or adverse outcomes [63].”
From Efficacy of oxytocin administration early after psychotrauma in preventing the development of PTSD: study protocol of a randomized controlled trial (2014) · cites this paper as [61]
Support for the notion that an effect size of d = 0.4 adequately reflects the potential of oxytocin to reduce psychiatric symptoms stems from 2 previous studies on long-term intranasal oxytocin administration in the treatment of positive and negative symptoms in schizophrenia patients.
“Support for the notion that an effect size of d = 0.4 adequately reflects the potential of oxytocin to reduce psychiatric symptoms stems from 2 previous studies on long-term intranasal oxytocin administration in the treatment of positive and negative symptoms in schizophrenia patients [61,97].”
From Efficacy of oxytocin administration early after psychotrauma in preventing the development of PTSD: study protocol of a randomized controlled trial (2014) · cites this paper as [61]
The observed effect sizes in those studies were between d = 0.05 - 0.88 and d = 0.24 - .74, depending on the outcome measure.
“The observed effect sizes were between d = 0.05 - 0.88 [97] and d = 0.24 -.74 (for most outcomes around d = 0.4) [61], depending on the outcome measure.”
From Efficacy of oxytocin administration early after psychotrauma in preventing the development of PTSD: study protocol of a randomized controlled trial (2014) · cites this paper as [61]
The BONDS trial's dose of 40 IU intranasal oxytocin was based on two studies that examined prolonged intranasal oxytocin administration on clinical symptoms in psychiatric patient populations and observed favorable outcomes.
“We based our dose of 40 IU on 2 studies that examined the effects of prolonged intranasal oxytocin administration on clinical symptoms in (psychiatric) patient populations and observed favorable outcomes [61,62].”
From Efficacy of oxytocin administration early after psychotrauma in preventing the development of PTSD: study protocol of a randomized controlled trial (2014) · cites this paper as [61]
Early investigations provide some encouragement that oxytocin could prove a useful supplement to current treatment of both schizophrenia and drug addiction.
“Interestingly, early investigations provide some encouragement that oxytocin could prove a useful supplement to current treatment of both schizophrenia (Keri et al., 2008;Feifel et al., 2010) and drug addiction (You et al., 2001;Qi et al., 2009;Carson et al., 2010).”
From Oxytocin enhances pupil dilation and sensitivity to 'hidden' emotional expressions (2013) · cites this paper as Feifel et al., 2010
Cites
Statistical Power Analysis for the Behavioral Sciences
Muller, K. E., & Cohen, J. (1989) · Technometrics · doi:10.2307/1270020 · Cited by 99,588 · see citing works
Statistical power analysis for the behavioral sciences
Cohen, J. (1990) · Computers Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,406 · see citing works
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378 · see citing works
Oxytocin increases trust in humans
Kosfeld, M., Heinrichs, M., Zak, P. J., Fischbacher, U., & Fehr, E. (2005) · Nature · doi:10.1038/nature03701 · Cited by 3,690 · see citing works
Theodoridou, A., Rowe, A. C., Penton-Voak, I. S., & Rogers, P. J. (2009) · Hormones and Behavior · doi:10.1016/j.yhbeh.2009.03.019 · Cited by 318 · see citing works
Ravina, B. M. (2005) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2004.050682 · Cited by 274 · see citing works
Goldman, M. B., Marlow-O’Connor, M., Torres, I. J., & Carter, C. S. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.09.019 · Cited by 211 · see citing works
Social Interaction Deficits Caused by Chronic Phencyclidine Administration are Reversed by Oxytocin
Lee, P. R., Brady, D. L., Shapiro, R. A., Dorsa, D. M., & Koenig, J. I. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300722 · Cited by 199 · see citing works
Sharing secrets: oxytocin and trust in schizophrenia
Kéri, S., Kiss, I., & Kelemen, O. (2009) · Social Neuroscience · doi:10.1080/17470910802319710 · Cited by 167 · see citing works
Vasopressin-oxytocin in cerebrospinal fluid of schizophrenic patients and normal controls
Beckmann, H., Lang, R. E., & Gattaz, W. F. (1985) · Psychoneuroendocrinology · doi:10.1016/0306-4530(85)90056-3 · Cited by 138 · see citing works
Oxytocin modulates psychotomimetic-induced deficits in sensorimotor gating
Feifel, D., & Reza, T. L. (1999) · Psychopharmacology · doi:10.1007/s002130050811 · Cited by 121 · see citing works
Self-citationOxytocin as a natural antipsychotic: a study using oxytocin knockout mice
Caldwell, H. K., Stephens, S. L., & Young, W. S. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002150 · Cited by 108 · see citing works
van Leeuwen, F. W., van Heerikhuize, J. J., van der Meulen, G., & Wolters, P. S. (1985) · Brain Research · doi:10.1016/0006-8993(85)91443-x · Cited by 95 · see citing works
Cerebrospinal fluid neurophysins in affective illness and in schizophrenia
Linkowski, P., Geenen, V. G., Kerkhofs, M., Mendlewicz, J., & Legros, J. J. (1984) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf00461555 · Cited by 89 · see citing works
Glovinsky, D., Kalogeras, K. T., Kirch, D. G., Suddath, R. L., & Wyatt, R. (1994) · Schizophrenia Research · doi:10.1016/0920-9964(94)90021-3 · Cited by 84 · see citing works
Legros, J. J., GAZZOTTI, C., Carvelli, T., Franchimont, P., Timsit-Berthier, M., von Frenckell, R., & Ansseau, M. (1992) · Psychoneuroendocrinology · doi:10.1016/0306-4530(92)90019-4 · Cited by 69 · see citing works
Jk, M., Berger, K., & Mv, S. (1993) · PubMed · Cited by 64 · see citing works
Is Oxytocin an Anti-Schizophrenic Hormone?
Bujanow, W. (1974) · Canadian Psychiatric Association Journal · doi:10.1177/070674377401900323 · Cited by 45 · see citing works
Psychotropic properties of oxytocin
Vd, B., Sm, T., & Lozhkina, T. K. (1986) · Neuroscience and Behavioral Physiology · doi:10.1007/bf01186517 · Cited by 27 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine
Meyer-Lindenberg, A., Domes, G., Kirsch, P., & Heinrichs, M. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3044 · Cited by 1,688 · see citing works
The oxytocin receptor: from intracellular signaling to behavior
Jurek, B., & Neumann, I. D. (2018) · Physiological Reviews · doi:10.1152/physrev.00031.2017 · Cited by 999 · see citing works
Increased brain and plasma oxytocin after nasal and peripheral administration in rats and mice
Neumann, I. D., Maloumby, R., Beiderbeck, D. I., Lukas, M., & Landgraf, R. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2013.03.003 · Cited by 511 · see citing works
Modulating social behavior with oxytocin: How does it work? What does it mean?
Churchland, P. S., & Winkielman, P. (2012) · Hormones and Behavior · doi:10.1016/j.yhbeh.2011.12.003 · Cited by 464 · see citing works
Vellante, M., Baron-Cohen, S., Melis, M., Marrone, M., Petretto, D. R., Masala, C., & Preti, A. (2013) · Cognitive Neuropsychiatry · doi:10.1080/13546805.2012.721728 · Cited by 406 · see citing works
Bakermans-Kranenburg, M. J., & van IJzendoorn, M. H. (2013) · Translational Psychiatry · doi:10.1038/tp.2013.34 · Cited by 383 · see citing works
Anagnostou, E., Soorya, L., Chaplin, W., Bartz, J., Halpern, D., Wasserman, S., Wang, A. T., Pepa, L., Tanel, N., Kushki, A., et al. (2012) · Molecular Autism · doi:10.1186/2040-2392-3-16 · Cited by 350 · see citing works
Pedersen, C. A., Gibson, C. M., Rau, S. W., Salimi, K., Smedley, K. L., Casey, R. L., Leserman, J., Jarskog, L. F., & Penn, D. L. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.07.027 · Cited by 305 · see citing works
De Dreu, C. K. W., & Kret, M. E. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.03.020 · Cited by 297 · see citing works
Prosocial effects of oxytocin and clinical evidence for its therapeutic potential
Striepens, N., Kendrick, K. M., Maier, W., & Hurlemann, R. (2011) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2011.07.001 · Cited by 283 · see citing works
Immunohistochemical localization of oxytocin receptors in human brain
Boccia, M. L., Petrusz, P., Suzuki, K., Marson, L., & Pedersen, C. A. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.08.048 · Cited by 276 · see citing works
Bales, K. L., Perkeybile, A. M., Conley, O. G., Lee, M. H., Guoynes, C. D., Downing, G. M., Yun, C. R., Solomon, M., Jacob, S., & Mendoza, S. P. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.08.025 · Cited by 265 · see citing works
Clinical and neural effects of six-week administration of oxytocin on core symptoms of autism
Watanabe, T., Kuroda, M., Kuwabara, H., Aoki, Y., Iwashiro, N., Tatsunobu, N., Takao, H., Nippashi, Y., Kawakubo, Y., Kunimatsu, A., et al. (2015) · Brain · doi:10.1093/brain/awv249 · Cited by 222 · see citing works
Chronic and acute intranasal oxytocin produce divergent social effects in mice
Huang, H., Michetti, C., Busnelli, M., Managò, F., Sannino, S., Scheggia, D., Giancardo, L., Sona, D., Murino, V., Chini, B., et al. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2013.310 · Cited by 199 · see citing works
Intranasal oxytocin blocks alcohol withdrawal in human subjects
Pedersen, C. A., Smedley, K. L., Leserman, J., Jarskog, L. F., Rau, S. W., Kampov‐Polevoi, A., Casey, R. L., Fender, T., & Garbutt, J. C. (2013) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2012.01958.x · Cited by 196 · see citing works
MacDonald, K., & Feifel, D. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00035 · Cited by 181 · see citing works
Self-citationWigton, R., Radua, J., Allen, P., Averbeck, B., Meyer-Lindenberg, A., McGuire, P., Shergill, S. S., & Fusar-Poli, P. (2015) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.130289 · Cited by 179 · see citing works
Intranasal administration of oxytocin: behavioral and clinical effects, a review
Veening, J. G., & Olivier, B. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.04.012 · Cited by 169 · see citing works
Oxytocin enhances pupil dilation and sensitivity to 'hidden' emotional expressions
Leknes, S., Wessberg, J., Ellingsen, D.-M., Chelnokova, O., Olausson, H., & Laeng, B. (2013) · Social Cognitive and Affective Neuroscience · doi:10.1093/scan/nss062 · Cited by 151 · see citing works
Tachibana, M., Kagitani-Shimono, K., Mohri, I., Yamamoto, T., Sanefuji, W., Nakamura, A., Oishi, M., Kimura, T., Onaka, T., Ozono, K., et al. (2013) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2012.0048 · Cited by 151 · see citing works
Rutigliano, G., Rocchetti, M., Paloyelis, Y., Gilleen, J., Sardella, A., Cappucciati, M., Palombini, E., Dell’Osso, L., Caverzasi, E., Politi, P., et al. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.04.117 · Cited by 149 · see citing works
“…of two recent clinical trials of exogenous OT (intranasal administration; dose: 24 IU twice daily (Pedersen et al., 2011) and 40 IU twice daily (Feifel et al., 2010)) in patients with schizophrenia suggest a therapeutic effect across different symptom domains with good safety and tolerability…”
Oxytocin-Augmented Social Cognitive Skills Training in Schizophrenia
Davis, M. C., Green, M. F., Lee, J., Horan, W. P., Senturk, D., Clarke, A. D., & Marder, S. R. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.68 · Cited by 149 · see citing works
Yamasue, H., Yee, J. R., Hurlemann, R., Rilling, J. K., Chen, F. S., Meyer-Lindenberg, A., & Tost, H. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.3327-12.2012 · Cited by 149 · see citing works
Effects of intranasal oxytocin on social anxiety in males with fragile X syndrome
Hall, S. S., Lightbody, A. A., McCarthy, B. E., Parker, K. J., & Reiss, A. L. (2012) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2011.07.020 · Cited by 143 · see citing works
Developmental experiences and the oxytocin receptor system
Bales, K. L., & Perkeybile, A. M. (2012) · Hormones and Behavior · doi:10.1016/j.yhbeh.2011.12.013 · Cited by 142 · see citing works
Intranasal Oxytocin Normalizes Amygdala Functional Connectivity in Posttraumatic Stress Disorder
Koch, S. B. J., van Zuiden, M., Nawijn, L., Frijling, J. L., Veltman, D. J., & Olff, M. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.1 · Cited by 132 · see citing works
MacDonald, K., MacDonald, T. M., Brüne, M., Lamb, K., Wilson, M. P., Golshan, S., & Feifel, D. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2013.05.014 · Cited by 140 · see citing works
Self-citationMetacognition, Self-Reflection and Recovery In Schizophrenia
Lysaker, P. H., Vohs, J. L., Ballard, R., Fogley, R., Salvatore, G., Popolo, R., & Dimaggio, G. (2013) · Future Neurology · doi:10.2217/fnl.12.78 · Cited by 134 · see citing works
Reduced levels of vasopressin and reduced behavioral modulation of oxytocin in psychotic disorders
Rubin, L. H., Carter, C. S., Bishop, J. R., Pournajafi-Nazarloo, H., Drogos, L. L., Hill, S. K., Ruocco, A. C., Keedy, S. K., Reilly, J. L., Keshavan, M. S., et al. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu027 · Cited by 127 · see citing works
Oxytocin, vasopressin, and the motivational forces that drive social behaviors
Caldwell, H. K., & Albers, H. E. (2015) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2015_390 · Cited by 129 · see citing works
Ebert, A., Kolb, M., Heller, J., Edel, M.-A., Roser, P., & Brüne, M. (2013) · Social Neuroscience · doi:10.1080/17470919.2013.807301 · Cited by 129 · see citing works
Effects of single dose intranasal oxytocin on social cognition in schizophrenia
Davis, M. C., Lee, J., Horan, W. P., Clarke, A. D., McGee, M. R., Green, M. F., & Marder, S. R. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.04.023 · Cited by 124 · see citing works
Cacciotti-Saija, C., Langdon, R., Ward, P. B., Hickie, I. B., Scott, E. M., Naismith, S. L., Moore, L., Alvares, G. A., Redoblado Hodge, M. A., & Guastella, A. J. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu094 · Cited by 119 · see citing works
Sex, Receptors, and Attachment: A Review of Individual Factors Influencing Response to Oxytocin
MacDonald, K. S. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2012.00194 · Cited by 119 · see citing works
Self-citationOxytocin administration enhances controlled social cognition in patients with schizophrenia
Woolley, J. D., Chuang, B., Lam, O., Lai, W., O’Donovan, A., Rankin, K. P., Mathalon, D. H., & Vinogradov, S. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2014.04.024 · Cited by 116 · see citing works
Kosaka, H., Okamoto, Y., Munesue, T., Yamasue, H., Inohara, K., Fujioka, T., Anme, T., Orisaka, M., Ishitobi, M., Jung, M., et al. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.152 · Cited by 117 · see citing works
Goldman, M. B., Gomes, A. M., Carter, C. S., & Lee, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2193-8 · Cited by 112 · see citing works
Vasopressin, oxytocin, and social odor recognition
Wacker, D. W., & Ludwig, M. (2012) · Hormones and Behavior · doi:10.1016/j.yhbeh.2011.08.014 · Cited by 112 · see citing works
Quintana, D. S., Westlye, L. T., Hope, S., Nærland, T., Elvsåshagen, T., Dørum, E., Rustan, Ø., Valstad, M., Rezvaya, L., Lishaugen, H., et al. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.103 · Cited by 111 · see citing works
A Review of Oxytocin’s Effects on the Positive, Negative, and Cognitive Domains of Schizophrenia
Feifel, D., Shilling, P. D., & MacDonald, K. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.07.025 · Cited by 110 · see citing works
Self-citationA brief history of oxytocin and its role in modulating psychostimulant effects
Carson, D. S., Guastella, A. J., Taylor, E. R., & McGregor, I. S. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881112473788 · Cited by 105 · see citing works
Prosocial effects of oxytocin in two mouse models of autism spectrum disorders
Teng, B. L., Nonneman, R. J., Agster, K. L., Nikolova, V. D., Davis, T. T., Riddick, N. V., Baker, L. K., Pedersen, C. A., Jarstfer, M. B., & Moy, S. S. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.04.038 · Cited by 98 · see citing works
Peptide therapeutics for CNS indications
McGonigle, P. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.10.014 · Cited by 95 · see citing works
Alvares, G. A., Quintana, D. S., & Whitehouse, A. J. O. (2017) · Autism Research · doi:10.1002/aur.1692 · Cited by 91 · see citing works
Oxytocin and vasopressin levels are decreased in the plasma of male schizophrenia patients
Jobst, A., Dehning, S., Ruf, S., Notz, T., Buchheim, A., Henning-Fast, K., Meißner, D., Meyer, S., Bondy, B., Müller, N., et al. (2014) · Acta Neuropsychiatrica · doi:10.1017/neu.2014.20 · Cited by 89 · see citing works
Lee, M. R., Wehring, H. J., McMahon, R. P., Linthicum, J., Cascella, N., Liu, F., Bellack, A., Buchanan, R. W., Strauss, G. P., Contoreggi, C., et al. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.01.001 · Cited by 80 · see citing works
Sobota, R., Mihara, T., Forrest, A., Featherstone, R. E., & Siegel, S. J. (2015) · Behavioral Neuroscience · doi:10.1037/bne0000074 · Cited by 80 · see citing works
Hicks, C., Jorgensen, W., Brown, C., Fardell, J., Koehbach, J., Gruber, C. W., Kassiou, M., Hunt, G. E., & McGregor, I. S. (2012) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2012.02311.x · Cited by 73 · see citing works
Oxytocin and vasopressin: signalling, behavioural modulation and potential therapeutic effects
Rae, M., Lemos Duarte, M., Gomes, I., Camarini, R., & Devi, L. A. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15481 · Cited by 72 · see citing works
Busnelli, M., Kleinau, G., Muttenthaler, M., Stoev, S., Manning, M., Bibic, L., Howell, L. A., McCormick, P. J., Di Lascio, S., Braida, D., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00564 · Cited by 67 · see citing works
Frijling, J. L., van Zuiden, M., Koch, S. B. J., Nawijn, L., Veltman, D. J., & Olff, M. (2016) · Social Cognitive and Affective Neuroscience · doi:10.1093/scan/nsv116 · Cited by 62 · see citing works
Effects of a 10-day oxytocin trial in older adults on health and well-being
Barraza, J. A., Grewal, N. S., Ropacki, S., Perez, P., Gonzalez, A., & Zak, P. J. (2013) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0031581 · Cited by 61 · see citing works
Frijling, J. L., van Zuiden, M., Koch, S. B., Nawijn, L., Goslings, J. C., Luitse, J. S., Biesheuvel, T. H., Honig, A., Bakker, F. C., Denys, D., et al. (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-92 · Cited by 59 · see citing works
Oxytocin nasal spray in fibromyalgic patients
Mameli, S., Pisanu, G. M., Sardo, S., Marchi, A., Pili, A., Carboni, M., Minerba, L., Trincas, G., Carta, M. G., Melis, M. R., et al. (2014) · Rheumatology International · doi:10.1007/s00296-014-2953-y · Cited by 54 · see citing works
Hofmann, S. G., Fang, A., & Brager, D. N. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.05.039 · Cited by 44 · see citing works
RetractedNeurochemical evidence for differential effects of acute and repeated oxytocin administration
Benner, S., Aoki, Y., Watanabe, T., Endo, N., Abe, O., Kuroda, M., Kuwabara, H., Kawakubo, Y., Takao, H., Kunimatsu, A., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-018-0249-4 · Cited by 40 · see citing works
Acheson, D. T., Feifel, D., Kamenski, M., Mckinney, R., & Risbrough, V. B. (2015) · Depression and Anxiety · doi:10.1002/da.22362 · Cited by 44 · see citing works
Self-citationTheodoridou, A., Rowe, A. C., & Mohr, C. (2013) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2013.00197 · Cited by 40 · see citing works
“…as individuals with alexithymia, social anxiety disorder, and schizophrenia (Caldwell et al., 2009; Guastella et al., 2009b; Bartz et al., 2010; Feifel et al., 2010; Rubin et al., 2010; Luminet et al., 2011; Pedersen et al., 2011; Hall et al., 2012) as it has already been shown in autism…”
BackgroundOxytocin as a potential therapeutic target for schizophrenia and other neuropsychiatric conditions
Feifel, D. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.184 · Cited by 42 · see citing works
Self-citationA human tendency to anthropomorphize is enhanced by oxytocin
Scheele, D., Schwering, C., Elison, J. T., Spunt, R., Maier, W., & Hurlemann, R. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.05.009 · Cited by 41 · see citing works
Quintana, D. S., Dieset, I., Elvsåshagen, T., Westlye, L. T., & Andreassen, O. A. (2017) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2016.12.004 · Cited by 39 · see citing works
Horta de Macedo, L. R., Zuardi, A. W., Machado-de-Sousa, J. P., Chagas, M. H. N., & Hallak, J. E. C. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.07.082 · Cited by 35 · see citing works
Oxytocin administration modulates rats’ helping behavior depending on social context
Yamagishi, A., Okada, M., Masuda, M., & Sato, N. (2020) · Neuroscience Research · doi:10.1016/j.neures.2019.04.001 · Cited by 33 · see citing works
Is oxytocin a promising treatment for schizophrenia?
Feifel, D. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.199 · Cited by 29 · see citing works
Self-citationOxytozin: Evidenz für ein therapeutisches Potenzial des sozialen Neuromodulators
Eckstein, M., & Hurlemann, R. (2013) · Der Nervenarzt · doi:10.1007/s00115-013-3832-6 · Cited by 28 · see citing works
Oxytocin: an expansive review of its mechanisms, functions, and therapeutic potential
Ueda, Y. (2023) · World Journal of Advanced Research and Reviews · doi:10.30574/wjarr.2023.19.1.1499 · Cited by 5 · see citing works
- Authors
- Feifel, D., Macdonald, K., Nguyen, A., Cobb, P., Warlan, H., Galangue, B., Minassian, A., Becker, O., Cooper, J., Perry, W., Lefebvre, M., Gonzales, J., & Hadley, A.
- Affiliations
- University of California San Diego Medical Center (US)
- Corresponding author
- Feifel, David
- Venue
- Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2010-10
- Volume
- 68
- Issue
- 7
- Pages
- 678-680
- ISSN
- 0006-3223 (ISSN-L)
- OpenAlex
- W1976654483
- Cited by
- 308
- References
- 19
- Citations by year
- 2026: 5 · 2025: 3 · 2024: 14 · 2023: 13 · 2022: 11 · 2021: 16 · 2020: 7 · 2019: 12 · 2018: 9 · 2017: 20 · 2016: 31 · 2015: 34 · 2014: 30 · 2013: 43 · 2012: 30
- FWCI
- 22.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biological Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Stanley Medical Research Institute
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Social Psychology › Neuroendocrine regulation and behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- oxytocin, schizophrenia, adjunctive therapy, residual symptoms, intranasal administration, positive and negative symptoms, treatment tolerability
- MeSH terms
- Administration, Intranasal, Adult, Double-Blind Method, Female, Humans, Male, Middle Aged, Oxytocin, Psychiatric Status Rating Scales, Schizophrenia, Schizophrenic Psychology, Antipsychotic Agents, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
